PHGDH and lung carcinoma: NCT503 was identified from the National Institutes of Health (NIH) Molecular Libraries Small Molecule Repository (MLSMR) drug library as a specific inhibitor of PHGDH [57]; it inhibited the malignant phenotype in breast, liver, and lung cancers in a PHGDH-dependent manner [55–57].